From co-morbidity to transdiagnostic potential and novel immunotherapies for psychosis.
From co-morbidity to transdiagnostic potential and novel immunotherapies for psychosis.
复制标题
从共病到跨诊断潜力和精神病的新型免疫疗法。
DOI：
10.1016/j.psychres.2022.114866
复制
发表时间：
2022
影响因子：
11.3
通讯作者：
Upthegrove,Rachel
中科院分区：
文献类型：
--
作者：
Upthegrove,Rachel
我第一次接受精神病学培训是在20世纪90年代末，在伯明翰参加精神病服务的早期干预。正是在这种情况下，我开始意识到情感共病的频率和重要性，以及在发展为严重精神疾病的早期阶段缺乏诊断的确定性。这挑战了情感性和非情感性严重精神疾病之间既定的二分法，并从那时起推动了我的工作和思考——包括接受精神分裂症中情感性症状的存在可能为新的治疗方法打开了大门。理解情感性功能障碍是发展为精神障碍的潜在内在组成部分，也显示了跨诊断症状的潜力，这些症状具有共同的潜在生物学过程，包括与缓解和功能结果相关的免疫功能障碍。目前，我的工作重点是针对免疫系统，以提高临床试验中的恢复，以及进一步超越传统诊断类别的机制研究。
One of my first placements in psychiatry training was with the early intervention in psychosis services in Birmingham, in the late 1990′s. It was in this context that I became aware of the frequency and importance of affective co- modbidity and lack of diagnostic certianty in early stages of develping severe mental illness. This challenged the established dichotomy between affective and non-affective severe mental illnesses, and has driven my work and thinking ever since- including that embracing the presence of affective symptoms in schizophrenia may open the door for new treatments. Understanding affective dysfunction as a potential intrisic component of developing psychotic disorders has also shown the potential for transdiagnostic symptoms with shared underlying biological processess, including immune dysfunction, related to remission and functional outcomes. Currently my work focuses on targeting the immune system to improve recovery in clinical trials, and further mechanistic studies that reach beyond traditional diagnostic catagories.